ADMS

Namzaric

Alzheimer's Dimentia

Quarterly Sales (Approved)

Exp Date

February 26, 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Namzaric for Alzheimer's disease 

  • **Adams receives royalties for this drug from Allergon**


MECHANISM OF ACTION

  • Namzaric contains active ingredients that are thought to block sustained activation of NMDA receptors caused by abnormal glutamatergic activity and slow the breakdown of acetylcholine to compensate for its loss

Updated by MV 

#Namzaric #ADMS #Adams #Alzheimers #Dimentia #autoimmunedisease #neurodegenerativecondition 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon